Aprogen
Founded Year
2000Stage
Reverse Merger | IPOTotal Raised
$62.12MAbout Aprogen
As of June 15, 2022, Aprogen merged with Aprogen Medicines. Aprogen is a Korean biopharmaceutical company that develops and manufactures biosimilars and biologics with its proprietary protein engineering technologies, including a patented bispecific antibody-engineering platform. Aprogen’s proprietary cell-engineering technology, combined with an advanced perfusion cell culture technology, ensures an extremely high yield of protein production in mammalian cell culture; multiple folds greater than that of the industry average. It was founded in 2000 and is based in Seongnam-Si, South Korea.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Aprogen Patents
Aprogen has filed 15 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/11/2020 | 1/3/2023 | Clusters of differentiation, Transcription factors, Olfactory receptors, Immunology, Immune system | Grant |
Application Date | 5/11/2020 |
|---|---|
Grant Date | 1/3/2023 |
Title | |
Related Topics | Clusters of differentiation, Transcription factors, Olfactory receptors, Immunology, Immune system |
Status | Grant |
Latest Aprogen News
Dec 30, 2022
Aprogen, which raised investors’ expectations by announcing acquiring a drug manufacturing facility in the U. S., has reversed the announcement and abandoned its acquisition.“In these times of global business slump, we thought the investment risk would increase sharply and decided not to push for th
Aprogen Frequently Asked Questions (FAQ)
When was Aprogen founded?
Aprogen was founded in 2000.
Where is Aprogen's headquarters?
Aprogen's headquarters is located at 545, Dunchon-daero, Seongnam-Si.
What is Aprogen's latest funding round?
Aprogen's latest funding round is Reverse Merger.
How much did Aprogen raise?
Aprogen raised a total of $62.12M.
Who are the investors of Aprogen?
Investors of Aprogen include Aprogen Medicines, Lindeman Asia Investment and Nichi-Iko Pharmaceutical.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
